Inhibrx Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Inhibrx Biosciences generated cash of -$193,309,000, which is less than the previous year. Cash used in financing activities reached the amount of $201,961,000 last year. Net change in cash is therefore $4,059,000.
Cash Flow
| 2016 | -18.10M | -215K | 28.76M |
|---|---|---|---|
| 2017 | -18.75M | -1.34M | 13.53M |
| 2018 | -23.09M | -1.42M | 13.15M |
| 2019 | -32.07M | -1.81M | 43.32M |
| 2020 | -47.96M | -1.36M | 166.45M |
| 2021 | -80.32M | -809K | 83.76M |
| 2022 | -115.30M | -686K | 258.55M |
| 2023 | -193.30M | -4.59M | 201.96M |
INBX Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 273.86M | 131.30M | 128.66M | 11.54M | 2.10M | 13.47M | 20.02M | 9.58M |
Operating activities | ||||||||
Net income | -241.36M | -145.22M | -81.76M | -76.12M | -51.4M | -31.02M | -22.08M | -8.26M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.19M | 1.22M | 1.19M | 1.01M | 1.16M | 676K | 399K | 253K |
Stock-based compensation expense | 24.84M | 17.79M | 15.04M | 5.02M | 3.97M | 2.48M | 1.18M | 552K |
| Deferred income tax benefit | 24.84M | 17.79M | 15.04M | 5.02M | 3.97M | 2.48M | 1.18M | 552K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -521K | 130K | -167K | 117K | 491K | -550K | -140K | 0 |
Inventories | 0 | 0 | -11.03M | 7.75M | -2.47M | -672K | 1.08M | 0 |
Accounts payable | 2.10M | -705K | -4.64M | 10.42M | -3.47M | 4.91M | 608K | 68K |
Cash generated by operating activities | -193.30M | -115.30M | -80.32M | -47.96M | -32.07M | -23.09M | -18.75M | -18.10M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -4.59M | -686K | -864K | -1.36M | -1.81M | -1.42M | -1.34M | -215K |
Acquisitions Net | 0 | 0 | 55K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -4.59M | -686K | -809K | -1.36M | -1.81M | -1.42M | -1.34M | -215K |
Financing activities | ||||||||
Common Stock Issued | 201.96M | 127.37M | 40.20M | 136.85M | 11.98M | 20.36M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | -828K | -1.37M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -39.99M | -5.45M | 0 | -5.68M | 0 | -13.76M |
Cash used in financing activities | 201.96M | 258.55M | 83.76M | 166.45M | 43.32M | 13.15M | 13.53M | 28.76M |
Net Change In Cash | 4.05M | 142.56M | 2.63M | 117.12M | 9.43M | -11.36M | -6.55M | 10.44M |
Cash at end of period | 277.92M | 273.86M | 131.30M | 128.66M | 11.54M | 2.10M | 13.47M | 20.02M |
| Data source | Data source | Data source | Data source |